Skip to main content
TipRanks
Go Ultimate75% OFF

Eurofins-Cerep Experiences Decrease in Revenue

Eurofins-Cerep Experiences Decrease in Revenue
Image source: Shutterstock

Eurofins-Cerep SA (FR:ALECR) has released an update.

Eurofins-Cerep SA reported a decrease in revenue for the first semester of 2024, down by 7.68% from the previous year, amid a contracting drug discovery market. Despite this, the company saw a positive financial result from cash investments and exchange rates, as well as progress in R&D with new pharmacological test applications and a biophysics platform for drug research. Looking ahead, the firm anticipates that renewed and developing contracts will mitigate turnover declines in the latter half of 2024.

For further insights into FR:ALECR stock, check out TipRanks’ Stock Analysis page.

This article was AI-generated from the company’s official filing, with automated quality checks and editorial spot-checks.

Disclaimer & DisclosureReport an Issue

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!